These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 21307649

  • 1. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT.
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [Abstract] [Full Text] [Related]

  • 2. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S.
    Vaccine; 2014 Jan 23; 32(5):624-30. PubMed ID: 24055350
    [Abstract] [Full Text] [Related]

  • 3. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
    Brown D, Müller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A.
    Vaccine; 2014 Oct 07; 32(44):5880-7. PubMed ID: 25148777
    [Abstract] [Full Text] [Related]

  • 4. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT.
    Hum Vaccin; 2008 Oct 07; 4(2):134-42. PubMed ID: 18388490
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
    Nygård M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, Sigurdardottir LG, Vuocolo S, Kjaer SK, Dillner J.
    Clin Vaccine Immunol; 2015 Aug 07; 22(8):943-8. PubMed ID: 26084514
    [Abstract] [Full Text] [Related]

  • 6. Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.
    Kahn JA, Xu J, Kapogiannis BG, Sleasman JW.
    J Acquir Immune Defic Syndr; 2017 Jun 01; 75(2):241-245. PubMed ID: 28291048
    [Abstract] [Full Text] [Related]

  • 7. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
    Roberts C, Green T, Hess E, Matys K, Brown MJ, Haupt RM, Luxembourg A, Vuocolo S, Saah A, Antonello J.
    Hum Vaccin Immunother; 2014 Jun 01; 10(8):2168-74. PubMed ID: 25424920
    [Abstract] [Full Text] [Related]

  • 8. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T, Liu Y, Li Y, Liao Y, Shou Q, Zheng M, Liao X, Li R.
    Vaccine; 2018 Mar 07; 36(11):1368-1374. PubMed ID: 29428178
    [Abstract] [Full Text] [Related]

  • 9. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2015 Mar 07; 11(3):732-8. PubMed ID: 25714044
    [Abstract] [Full Text] [Related]

  • 10. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, Penny ME, Restrepo JA, Romaguera J, Maansson R, Moeller E, Ritter M, Chen J.
    Hum Vaccin Immunother; 2015 Mar 07; 11(6):1313-22. PubMed ID: 25912208
    [Abstract] [Full Text] [Related]

  • 11. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH, Levin MJ, Chatterjee A, Chakhtoura N, Takacs P, Catteau G, Dessy FJ, Moris P, Lin L, Struyf F, Dubin G, HPV-010 Study Group.
    Hum Vaccin Immunother; 2014 Mar 07; 10(12):3455-65. PubMed ID: 25483700
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
    Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, Dobson S, Ogilvie G, Petric M.
    Clin Vaccine Immunol; 2011 Mar 07; 18(3):418-23. PubMed ID: 21248158
    [Abstract] [Full Text] [Related]

  • 13. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
    Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, Barr E, Brown DR, Bryan JT.
    Hum Vaccin; 2007 Mar 07; 3(4):109-15. PubMed ID: 17611417
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
    Praditpornsilpa K, Kingwatanakul P, Deekajorndej T, Rianthavorn P, Susantitaphong P, Katavetin P, Tiranathanakul K, Srisawat N, Tungsanga K, Eiam-Ong S, Townamchai N.
    Nephrol Dial Transplant; 2017 Jan 01; 32(1):132-136. PubMed ID: 26932687
    [Abstract] [Full Text] [Related]

  • 15. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 16. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.
    PLoS One; 2013 Jul 15; 8(5):e61825. PubMed ID: 23650505
    [Abstract] [Full Text] [Related]

  • 17. Multiplexed serologic assay for nine anogenital human papillomavirus types.
    Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT.
    Clin Vaccine Immunol; 2010 May 15; 17(5):818-27. PubMed ID: 20237197
    [Abstract] [Full Text] [Related]

  • 18. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P, Matsui K, Wong M, Alvarez J, Lambert P, Christensen ND, Hu J, Huber B, Kirnbauer R, Wang JW, Roden RBS.
    J Virol; 2022 Jul 13; 96(13):e0056622. PubMed ID: 35703545
    [Abstract] [Full Text] [Related]

  • 19. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M.
    Pediatr Infect Dis J; 2015 Sep 13; 34(9):992-8. PubMed ID: 26090572
    [Abstract] [Full Text] [Related]

  • 20. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.
    PLoS One; 2014 Sep 13; 9(7):e101576. PubMed ID: 24999962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.